Official websites use. Share sensitive information only on official, secure websites. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.
If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. While targeted temperature management TTM has been recommended in patients with shockable cardiac arrest CA and suggested in patients with non-shockable rhythms, few data exist regarding the impact of the rewarming rate on systemic inflammation. We randomized 50 patients.
The median IL6 area-under-the-curve was similar between the two groups 12, [β37,] vs. Median NF-L levels were not significantly different between the 0.
Trial registration ClinicalTrials. Registered September 14, Take-Home Message : Rewarming at a rate of 0. No associations were found between the slower rewarming rate and day functional outcomes or mortality. Keywords: Cardiac arrest, Targeted temperature management, Therapeutic hypothermia. Moreover, the use of targeted temperature management TTM remains variable [ 1 , 2 ], probably due in part to the paucity or poor quality of data on TTM strategies [ 3 , 4 ].
That studies have produced conflicting efficacy data may be related to differences in various TTM components including rewarming parameters. Rewarming may be associated with myocardial function deterioration, a mismatch in oxygen consumption vs. The most clinically significant rewarming parameter may be the rate of the temperature increase, which was 0. To date, no randomized controlled trials RCTs have compared different rewarming rates.
